This article is more than 5 years old. Information may no longer be current.
Chemotherapy offered limited benefit for advanced chondrosarcomas
Click Here to Manage Email Alerts
Conventional chemotherapy demonstrated limited efficacy in patients with advanced chondrosarcomas, with the highest benefit found in mesenchymal and dedifferentiated subtypes, according to study results.
Limited data exist with regard to the effects of chemotherapy in patients with advanced chondrosarcomas, researchers said.
Antoine Italiano, MD, PhD, and colleagues from the Institut Bergonié in Bordeaux, France, reviewed the medical charts of 180 patients with advanced chondrosarcomas who received chemotherapy at 15 participating institutions between 1988 and 2011.
Sixty-three percent of patients had conventional chondrosarcoma and 88% had metastatic disease. Ninety-eight patients (54.5%) received combination chemotherapy, and 131 patients (73%) received an anthracycline-containing regimen.
Analysis with RECIST criteria showed the objective response rate varied significantly by histological subtype. Italiano and colleagues reported response rates of 31% for mesenchymal chondrosarcoma, 20.5% for dedifferentiated chondrosarcoma, 11.5% for conventional chondrosarcoma and 0% for clear-cell chondrosarcoma (P=.04).
Median PFS was 4.7 months (95% CI, 3-6.5). Several factors — including performance status of at least 2, at least one metastatic site and receipt of a single-agent regimen — were independently linked to poor PFS.
Median OS was 18 months (95% CI, 14.5-21.6). Performance status, number of metastatic sites and palliative surgery each were independently associated with OS.
The data should be used as a reference for response and outcome in the assessment of investigational drugs in advanced chondrosarcoma, Italiano and colleagues concluded.
Disclosure: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts